{"id":51550,"date":"2020-03-22T01:00:00","date_gmt":"2020-03-22T05:00:00","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=51550"},"modified":"2022-11-29T16:00:24","modified_gmt":"2022-11-29T21:00:24","slug":"dot-releases-guidance-on-compliance-with-drug-and-alcohol-testing-regulations-during-pandemic","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/dot-releases-guidance-on-compliance-with-drug-and-alcohol-testing-regulations-during-pandemic\/","title":{"rendered":"Drug and Alcohol Testing Regulations During Pandemic. DOT Update"},"content":{"rendered":"\n<p><strong><a href=\"\/dot-compliance\/\">The Department of Transportation (DOT)<\/a> is committed to maintaining public safety while providing maximum flexibility to allow transportation industries to conduct their operations safely and efficiently during this period of national emergency.<\/strong><\/p>\n\n\n\n<p>The bottom line is that <a href=\"https:\/\/www.nationaldrugscreening.com\/dot-drug-test\/\"><strong>DOT regulated companies<\/strong><\/a> should continue testing those in safety-sensitive positions. Below is guidance on compliance with the DOT and modal drug and alcohol testing programs during this period of national emergency.<\/p>\n\n\n\n<p><strong>For DOT-Regulated Employers:<\/strong><\/p>\n\n\n\n<ul>\n<li><strong>As a DOT-regulated employer, you must comply with applicable DOT training and testing requirements.<\/strong> However, DOT recognizes that compliance may not be possible in certain areas due to the unavailability of program resources, such as collection sites, Breath Alcohol Technicians (BAT), <strong><a href=\"https:\/\/www.nationaldrugscreening.com\/mro-service\/\">Medical Review Officers (MRO)<\/a><\/strong>, and Substance Abuse Professionals (SAP). You should make a reasonable effort to locate the necessary resources. As a best practice at this time, employers should consider mobile collection services for required testing if the fixed-site collection facilities are not available.<\/li>\n\n\n\n<li><strong>If you are unable to conduct DOT drug or alcohol training or testing due to COVID-19<\/strong>&#8211; related supply shortages, facility closures, State or locally imposed quarantine requirements, or other impediments, you are to continue to comply with existing applicable DOT Agency requirements to document why a test was not completed. If the training or testing can be conducted later (e.g., supervisor reasonable suspicion training at the next available opportunity, random testing later in the selection period, follow-up testing later in the month), you are to do so in accordance with applicable modal regulations. Links to the modal regulations and their respective web pages can be found at <a href=\"https:\/\/www.transportation.gov\/odapc\/agencies\">https:\/\/www.transportation.gov\/odapc\/agencies.<\/a><\/li>\n\n\n\n<li><em><strong>If employers are unable to conduct DOT drug and alcohol testing due to the unavailability of testing resources<\/strong>, the underlying modal regulations continue to apply. <\/em>For example, without a \u201cnegative\u201d pre-employment drug test result, an employer may not permit a prospective or current employee to perform any DOT safety-sensitive functions,or in the case of the Federal Aviation Administration (FAA), you cannot hire the individual (See 14 CFR \u00a7 120.109(1) and (2)).<\/li>\n\n\n\n<li><strong>Additionally, DOT is aware that some employees have expressed concern about potential public health risks<\/strong> associated with the collection and testing process in the current environment. Employers should review the applicable DOT Agency requirements for testing to determine whether flexibilities allow for collection and testing at a later date.<\/li>\n\n\n\n<li><strong>As a reminder, it is the <u>employer\u2019s<\/u> responsibility to evaluate the circumstances of the employee\u2019s refusal to test<\/strong> and determine whether or not the employee\u2019s actions should be considered a refusal as per 49 CFR 40.355(i). However, as the COVID-19 outbreak poses a novel public health risk, DOT asks employers to be sensitive to employees who indicate they are not comfortable or are afraid to go to clinics or collection sites. DOT asks employers to verify with the clinic or collection site that it has taken the necessary precautions to minimize the risk of exposure to COVID-19.<\/li>\n\n\n\n<li><strong>Employers should revisit back-up plans to ensure the plans are current and effective for the current outbreak conditions.<\/strong> For example, these plans should include the availability of collectors and collection sites and BAT, and alternate\/back-up MRO, as these may have changed as a result of the national emergency. Employers should also have regular communications with service agents regarding the service agent\u2019s availability and capability to support your DOT drug and alcohol testing.<\/li>\n<\/ul>\n\n\n\n<p><a href=\"\/wp-content\/uploads\/2020\/06\/dot-guidance-on-compliance-with-drug-and-alcohol-testing-regulations.pdf\">Read the Full Guidance here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Department of Transportation (DOT) is committed to maintaining public safety while providing maximum flexibility to allow transportation industries to conduct their operations safely and efficiently during this period of national emergency. The bottom line is that DOT regulated companies should continue testing those in safety-sensitive positions. Below is guidance on compliance with the DOT [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":54143,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"50865,51047,51539,51568,50873,50940","_relevanssi_noindex_reason":"","footnotes":""},"categories":[46,68,80,47],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51550"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=51550"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/54143"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=51550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=51550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=51550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}